Skip to Main content Skip to Navigation
Journal articles

Effect of desipramine on patients with breathing disorders in RETT syndrome

Josette Mancini 1 Jean-Christophe Dubus 2 Elisabeth Jouve 3 Jean-Christophe Roux 4 Patricia Franco 5 Emmanuelle Lagrue 6 Pierre Castelnau 6 Claude Cances 7 Yves Chaix 8 Christelle Rougeot-Jung Catherine Cornu 9 Vincent Desportes Louis Vallée 10 Nadia Bahi-Buisson 11 Romain Truillet 3 Laurence Attolini Laurent Villard 12, 4 Olivier Blin 13 Joëlle Micallef 14
1 TIMONE - Hôpital de la Timone [CHU - APHM]
2 MEPHI - Microbes évolution phylogénie et infections
3 CIC - Centre d'Investigation Clinique [Hôpital de la Conception - APHM]
4 MMG - Marseille medical genetics - Centre de génétique médicale de Marseille
5 Physiologie integrée du système d'éveil
6 iBrain - Inserm U1253 - UNIV Tours - Imagerie et cerveau
7 Département de Pédiatrie
8 ToNIC - Toulouse Neuro Imaging Center
9 CIC CHU Lyon (inserm)
10 Service de Neuropédiatrie
11 Service de neurologie pédiatrique [CHU Necker]
12 Département de génétique médicale [Hôpital de la Timone - APHM]
13 Clinical Investigation Centre (CIC-UPCET) and Department of Clinical Pharmacology,
CIC-UPCET - Centre investigation clinique - Unité de pharmacologie clinique et d'évaluations thérapeutiques
14 EuroMov - Euromov
Abstract : Objective: Rett Syndrome (RTT) is a severe neurodevelopmental condition with breathing disorders, affecting around one in 10,000 female births. Desipra-mine, a noradrenaline reuptake inhibitor, reduced the number of apneas in Mecp2-deficient mice, a model of RTT. We planned a phase 2 trial to test its efficacy and its safety on breathing patterns in 36 girls with RTT. Methods: The trial was a 6-month, multicenter, randomized, double-blind, placebo-controlled study registered with ClinicalTrials.gov, number NCT00990691. Girls diagnosed according to clinical examination and confirmed by genotyping were randomly assigned in a 1:1:1 ratio to receive 2–3 mg/kg Desipramine per day (high Desi-pramine), 1–2 mg/kg Desipramine per day (low Desipramine), or a placebo. The primary outcome was the change of apnea hypopnea index (AHI), defined by the number of apnea and hypopnea events per hour, assessed at 6 months from baseline. Intention-to-treat analysis was applied. Results: The median change in AHI from baseline to 6 months was À31 (IQR: À37 to À11) for the high Desipramine, À17.5 (IQR: À31 to 13) for the low Desipramine, and À13 (IQR:À31 to 0) for the placebo group. We did not find any significant difference in these changes between the groups (P = 0.781). A significant inverse correlation between Desipramine plasma concentration and AHI (r = À0.44; P = 0.0002) was underlined. Interpretation: This first clinical trial of desipra-mine did not show clinical efficacy. Although required further studies, the significant correlation between Desipramine concentrations and improvement of AHI provided additional and relevant reasons to test the noradrenergic pathway in RTT. 118
Document type :
Journal articles
Complete list of metadata

Cited literature [30 references]  Display  Hide  Download
https://hal-amu.archives-ouvertes.fr/hal-01718409
Contributor : Jean-Christophe Roux <>
Submitted on : Wednesday, March 28, 2018 - 5:19:13 PM
Last modification on : Thursday, May 27, 2021 - 5:08:03 PM
Long-term archiving on: : Thursday, September 13, 2018 - 12:18:39 PM

File

Vignette du document
Mancini_et_al-2018-Annals_of_C...
Publisher files allowed on an open archive

Identifiers

Collections

UNIV-AMU | UNIV-TOURS | INSERM | UNIV-MONTPELLIER | BS | UNIV-LYON1 | IFNL | CNRS | IRD | MMG | UNIV-TLSE3 | UDL

Citation

Josette Mancini, Jean-Christophe Dubus, Elisabeth Jouve, Jean-Christophe Roux, Patricia Franco, et al.. Effect of desipramine on patients with breathing disorders in RETT syndrome. Annals of Clinical and Translational Neurology, Wiley, 2018, 5 (2), pp.118 - 127. ⟨10.1002/acn3.468⟩. ⟨hal-01718409⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

698

Files downloads

565